Skip to main content
Top
Published in: BMC Cancer 1/2004

Open Access 01-12-2004 | Software

An electronic application for rapidly calculating Charlson comorbidity score

Authors: William H Hall, Ramanathan Ramachandran, Samir Narayan, Ashesh B Jani, Srinivasan Vijayakumar

Published in: BMC Cancer | Issue 1/2004

Login to get access

Abstract

Background

Uncertainty regarding comorbid illness, and ability to tolerate aggressive therapy has led to minimal enrollment of elderly cancer patients into clinical trials and often substandard treatment. Increasingly, comorbid illness scales have proven useful in identifying subgroups of elderly patients who are more likely to tolerate and benefit from aggressive therapy. Unfortunately, the use of such scales has yet to be widely integrated into either clinical practice or clinical trials research.

Methods

This article reviews evidence for the validity of the Charlson Comorbidity Index (CCI) in oncology and provides a Microsoft Excel (MS Excel) Macro for the rapid and accurate calculation of CCI score. The interaction of comorbidity and malignant disease and the validation of the Charlson Index in oncology are discussed.

Results

The CCI score is based on one year mortality data from internal medicine patients admitted to an inpatient setting and is the most widely used comorbidity index in oncology. An MS Excel Macro file was constructed for calculating the CCI score using Microsoft Visual Basic. The Macro is provided for download and dissemination.
The CCI has been widely used and validated throughout the oncology literature and has demonstrated utility for most major cancers. The MS Excel CCI Macro provides a rapid method for calculating CCI score with or without age adjustments. The calculator removes difficulty in score calculation as a limitation for integration of the CCI into clinical research. The simple nature of the MS Excel CCI Macro and the CCI itself makes it ideal for integration into emerging electronic medical records systems.

Conclusions

The increasing elderly population and concurrent increase in oncologic disease has made understanding the interaction between age and comorbid illness on life expectancy increasingly important. The MS Excel CCI Macro provides a means of increasing the use of the CCI scale in clinical research with the ultimate goal of improving determination of optimal treatments for elderly cancer patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hall SF, Rochon PA, Streiner DL, Paszat LF, Groome PA, Rohland SL: Measuring comorbidity in patients with head and neck cancer. Laryngoscope. 2002, 112: 1988-1996. 10.1097/00005537-200211000-00015.CrossRefPubMed Hall SF, Rochon PA, Streiner DL, Paszat LF, Groome PA, Rohland SL: Measuring comorbidity in patients with head and neck cancer. Laryngoscope. 2002, 112: 1988-1996. 10.1097/00005537-200211000-00015.CrossRefPubMed
2.
go back to reference Extermann M: Measuring comorbidity in older cancer patients. Eur J Cancer. 2000, 36: 453-471. 10.1016/S0959-8049(99)00319-6.CrossRefPubMed Extermann M: Measuring comorbidity in older cancer patients. Eur J Cancer. 2000, 36: 453-471. 10.1016/S0959-8049(99)00319-6.CrossRefPubMed
3.
go back to reference Extermann M: Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000, 35: 181-200.CrossRefPubMed Extermann M: Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000, 35: 181-200.CrossRefPubMed
4.
go back to reference de Groot V, Beckerman H, Lankhorst G, Bouter L: How to measure comorbidity: a critical review of available methods. J Clin Epidmiol. 2003, 56: 221-229. 10.1016/S0895-4356(02)00585-1.CrossRef de Groot V, Beckerman H, Lankhorst G, Bouter L: How to measure comorbidity: a critical review of available methods. J Clin Epidmiol. 2003, 56: 221-229. 10.1016/S0895-4356(02)00585-1.CrossRef
5.
go back to reference Feinstein AR: Symptomatic patterns, biologic behavior, and prognosis in cancer of the lung: Practical application of Boolean Algebra and clinical taxonomy. Ann Intern Med. 1964, 61: 27-43.CrossRefPubMed Feinstein AR: Symptomatic patterns, biologic behavior, and prognosis in cancer of the lung: Practical application of Boolean Algebra and clinical taxonomy. Ann Intern Med. 1964, 61: 27-43.CrossRefPubMed
6.
go back to reference Hall SF, Groome PA, Rothwell D: The impact of comorbidity on survival of patients with squamous cell carcinoma of the head and neck. Head and Neck. 1999, 22: 317-322. 10.1002/1097-0347(200007)22:4<317::AID-HED1>3.0.CO;2-0.CrossRef Hall SF, Groome PA, Rothwell D: The impact of comorbidity on survival of patients with squamous cell carcinoma of the head and neck. Head and Neck. 1999, 22: 317-322. 10.1002/1097-0347(200007)22:4<317::AID-HED1>3.0.CO;2-0.CrossRef
7.
go back to reference Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994, 120: 104-10.CrossRefPubMed Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994, 120: 104-10.CrossRefPubMed
8.
go back to reference Post PN, Hansen BE, Kil PJM, Janssen-Heijnen MLG, Coebergh JWW: The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: a population-based study. BJU Int. 2001, 87: 821-826. 10.1046/j.1464-410x.2001.02189.x.CrossRefPubMed Post PN, Hansen BE, Kil PJM, Janssen-Heijnen MLG, Coebergh JWW: The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: a population-based study. BJU Int. 2001, 87: 821-826. 10.1046/j.1464-410x.2001.02189.x.CrossRefPubMed
9.
go back to reference Yancik R, Wesley M, Ries LAG, Havlik RJ, Long S, Edwards BK, Yates JW: Comorbidity and age as predictors of early mortality of male and female colon carcinoma patients. A population based study. Cancer. 1998, 82: 2123-34.CrossRefPubMed Yancik R, Wesley M, Ries LAG, Havlik RJ, Long S, Edwards BK, Yates JW: Comorbidity and age as predictors of early mortality of male and female colon carcinoma patients. A population based study. Cancer. 1998, 82: 2123-34.CrossRefPubMed
10.
go back to reference De Marco MF, Janssen-Heijnen MLG, van der Heijden LH, Coebergh JWW: Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer. 2000, 36: 95-99. 10.1016/S0959-8049(99)00221-X.CrossRefPubMed De Marco MF, Janssen-Heijnen MLG, van der Heijden LH, Coebergh JWW: Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer. 2000, 36: 95-99. 10.1016/S0959-8049(99)00221-X.CrossRefPubMed
11.
go back to reference Firat S, Byhardt RW, Gore E: Comorbidity and Karnofsky Performance Score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys. 2002, 54: 357-364. 10.1016/S0360-3016(02)02939-5.CrossRefPubMed Firat S, Byhardt RW, Gore E: Comorbidity and Karnofsky Performance Score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys. 2002, 54: 357-364. 10.1016/S0360-3016(02)02939-5.CrossRefPubMed
12.
go back to reference Piccirillo JF, Costas I, Claybour P, Borah AJ, Grove L, Jeffe D: The Measurement of comorbidity in cancer regisitries. J of Registry Management. 2003, 30: 8-14. Piccirillo JF, Costas I, Claybour P, Borah AJ, Grove L, Jeffe D: The Measurement of comorbidity in cancer regisitries. J of Registry Management. 2003, 30: 8-14.
13.
go back to reference Charlson ME, Pompei P, Ales K, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987, 40: 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed Charlson ME, Pompei P, Ales K, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987, 40: 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed
14.
go back to reference Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, Har-El G, Lucente FE: Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. The Laryngoscope. 1997, 107: 1469-1475. 10.1097/00005537-199711000-00009.CrossRefPubMed Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, Har-El G, Lucente FE: Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. The Laryngoscope. 1997, 107: 1469-1475. 10.1097/00005537-199711000-00009.CrossRefPubMed
15.
go back to reference Fowler JE, Terrell FL, Refroe LC: Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J of Urology. 1996, 156: 1714-1718. 10.1097/00005392-199611000-00045.CrossRef Fowler JE, Terrell FL, Refroe LC: Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J of Urology. 1996, 156: 1714-1718. 10.1097/00005392-199611000-00045.CrossRef
16.
go back to reference Albertsen PC, Hanley JA, Gleason DF, Barry MJ: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998, 280: 975-980. 10.1001/jama.280.11.975.CrossRefPubMed Albertsen PC, Hanley JA, Gleason DF, Barry MJ: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998, 280: 975-980. 10.1001/jama.280.11.975.CrossRefPubMed
17.
go back to reference Hall W, Ashesh JB, Ryu JK, Narayan S, Vijayakumar S: The impact of age and comorbidity on survival and treatment patterns in prostate cancer: using the Charlson Comorbidity Index to improve outcomes. In Progress. 2003 Hall W, Ashesh JB, Ryu JK, Narayan S, Vijayakumar S: The impact of age and comorbidity on survival and treatment patterns in prostate cancer: using the Charlson Comorbidity Index to improve outcomes. In Progress. 2003
18.
go back to reference Firat S, Bousamra M, Gore E, Byhardt RW: Comorbidity and KPS are independent prognostic factos in stage I non-small-cell lung cancer. Int J Radiation Oncology Biol Phys. 2002, 52: 1047-1057. 10.1016/S0360-3016(01)02741-9.CrossRef Firat S, Bousamra M, Gore E, Byhardt RW: Comorbidity and KPS are independent prognostic factos in stage I non-small-cell lung cancer. Int J Radiation Oncology Biol Phys. 2002, 52: 1047-1057. 10.1016/S0360-3016(01)02741-9.CrossRef
19.
go back to reference Birim Ö, Maat APWM, Kappetein AP, van Meerbeeck JP, Damhuis RA, Bogers AJ: Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardiothorac Surg. 2003, 23: 30-34. 10.1016/S1010-7940(02)00721-2.CrossRefPubMed Birim Ö, Maat APWM, Kappetein AP, van Meerbeeck JP, Damhuis RA, Bogers AJ: Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardiothorac Surg. 2003, 23: 30-34. 10.1016/S1010-7940(02)00721-2.CrossRefPubMed
20.
go back to reference Rieker JR, Hammer E, Eisele R, Schmid E, Hogel J: The impact of comorbidity on the overall survival and the cause of death in patients after colorectal cancer resection. Langenbeck's Arch Surg. 2002, 387: 72-76. 10.1007/s00423-002-0291-0.CrossRef Rieker JR, Hammer E, Eisele R, Schmid E, Hogel J: The impact of comorbidity on the overall survival and the cause of death in patients after colorectal cancer resection. Langenbeck's Arch Surg. 2002, 387: 72-76. 10.1007/s00423-002-0291-0.CrossRef
21.
go back to reference Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999, 341: 2061-2067. 10.1056/NEJM199912303412706.CrossRefPubMed Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999, 341: 2061-2067. 10.1056/NEJM199912303412706.CrossRefPubMed
22.
go back to reference Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003, 21: 1383-1389. 10.1200/JCO.2003.08.010.CrossRefPubMed Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003, 21: 1383-1389. 10.1200/JCO.2003.08.010.CrossRefPubMed
23.
go back to reference Yancik R: Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997, 80: 1273-1283.CrossRefPubMed Yancik R: Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997, 80: 1273-1283.CrossRefPubMed
24.
go back to reference Yancik R, Ries LA: Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000, 14: 17-23.CrossRefPubMed Yancik R, Ries LA: Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000, 14: 17-23.CrossRefPubMed
25.
go back to reference Extermann M, Overcash J, Lyman GH, Parr L, Balducci L: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998, 16: 1582-1587.PubMed Extermann M, Overcash J, Lyman GH, Parr L, Balducci L: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998, 16: 1582-1587.PubMed
26.
go back to reference Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Varicelli M, Parodi S, Dal Lago D, Gioia F, Monfardini S, Aapro MS, Serraino D, Zagonel V: Comprehensive Geriatric Assesment adds information to Eastern Cooperative Oncology Group Performance Status An Italian Group for Geriatric Oncology study. J Clin Oncol. 2002, 20: 494-502. 10.1200/JCO.20.2.494.CrossRefPubMed Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Varicelli M, Parodi S, Dal Lago D, Gioia F, Monfardini S, Aapro MS, Serraino D, Zagonel V: Comprehensive Geriatric Assesment adds information to Eastern Cooperative Oncology Group Performance Status An Italian Group for Geriatric Oncology study. J Clin Oncol. 2002, 20: 494-502. 10.1200/JCO.20.2.494.CrossRefPubMed
27.
go back to reference Chin T: Americans trail much of Europe in adopting EMRs. American Medical News. 34-September 2, 2002 Chin T: Americans trail much of Europe in adopting EMRs. American Medical News. 34-September 2, 2002
28.
go back to reference Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, Boyle D, Leape L: The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc. 1999, 6: 313-321.CrossRefPubMedPubMedCentral Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, Boyle D, Leape L: The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc. 1999, 6: 313-321.CrossRefPubMedPubMedCentral
29.
go back to reference Hunt DL, Haynes RB, Hanna SE, Smith K: Effects of computer-based clinical decision support systems on physician performance and patient outcomes. JAMA. 1998, 280: 1339-1346. 10.1001/jama.280.15.1339.CrossRefPubMed Hunt DL, Haynes RB, Hanna SE, Smith K: Effects of computer-based clinical decision support systems on physician performance and patient outcomes. JAMA. 1998, 280: 1339-1346. 10.1001/jama.280.15.1339.CrossRefPubMed
30.
go back to reference Extermann M, Overcash J, Lyman GH, Parr J, Balducci L: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998, 16: 1582-1587.PubMed Extermann M, Overcash J, Lyman GH, Parr J, Balducci L: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998, 16: 1582-1587.PubMed
Metadata
Title
An electronic application for rapidly calculating Charlson comorbidity score
Authors
William H Hall
Ramanathan Ramachandran
Samir Narayan
Ashesh B Jani
Srinivasan Vijayakumar
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2004
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-4-94

Other articles of this Issue 1/2004

BMC Cancer 1/2004 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine